866-997-4948(US-Canada Toll Free)

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 62 Pages

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2017

Summary

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2017, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 9 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Prostate Cancer, Pancreatic Cancer, Bladder Cancer, Melanoma, Autoimmune Disorders, Bone Metastasis, Colorectal Cancer, Breast Cancer, Colon Carcinoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Ovarian Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development
Biomics Biotechnologies Co Ltd
Bioneer Corp
Boehringer Ingelheim GmbH
MimiVax LLC
Optimum Therapeutics LLC
Polyplus-Transfection SA
Vaxeal Holding SA
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1644 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1740 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Target Survivin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Survivin for Oncology and Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UC-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Lymphoma and Colon Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Survivin for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Survivin for Breast Cancer and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones
Featured News & Press Releases
May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID to Treat Rare Blood Cancer
Sep 09, 2015: Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
Apr 21, 2015: SurVaxM Phase I Completed
Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
Nov 04, 2013: CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer
Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Pipeline by Bioneer Corp, H2 2017
Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pipeline by MimiVax LLC, H2 2017
Pipeline by Optimum Therapeutics LLC, H2 2017
Pipeline by Polyplus-Transfection SA, H2 2017
Pipeline by Vaxeal Holding SA, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *